Senate Bill 765 aims to prohibit insurers, pharmacy benefit managers, and utilization review organizations from implementing step therapy protocols for certain cancer drugs. Specifically, the bill targets drugs prescribed for metastatic cancer or cancer-associated conditions, provided that these drugs are approved by the federal Food and Drug Administration (FDA), align with best practices for treatment, and are supported by peer-reviewed, evidence-based research. The bill also renumbers existing legal language and introduces new definitions for "cancer-associated condition" and "metastatic cancer" to clarify the scope of the legislation.

The bill includes several key insertions into the statutes, such as the creation of definitions for "cancer-associated condition" and "metastatic cancer," which describe the health implications of these conditions. Additionally, it establishes a new provision that explicitly prohibits the use of step therapy protocols for the specified drugs, ensuring that patients have direct access to necessary treatments without being subjected to potentially burdensome prior authorization processes.